Talk to your doctor today to find out whether you or a loved one may be eligible to receive ABO-101 through the redePHine trial.
For more information, visit www.clinicaltrials.gov (NCT06839235) or the redePHine trial site.
Primary hyperoxalurias are a group of rare metabolic disorders characterized by overproduction of oxalate.
The most prevalent type is PH1, caused by an inherited mutation in the AGXT gene.
PH1 affects 1–3 people per million in North America and Europe and has the highest prevalence in the Middle East and North Africa.
The redePHine Phase 1/2 study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO-101 in both adult and pediatric patients with PH1.
Learn more about clinical trial enrollment and trial sites here.
ABO-101 is a novel, investigational gene editing medicine designed to be a one-time treatment that results in a permanent loss of function of the HAO1 gene in the liver to reduce PH1-associated oxalate production. ABO-101 consists of a lipid nanoparticle (LNP)* messenger RNA expressing a novel Type V CRISPR Cas12i2 nuclease and an optimized guide RNA which specifically targets the human HAO1 gene.
Learn more about gene editing for PH1 here.
*Licensed from Acuitas Therapeutics
